
MEDIA INFORMATION

FOR IMMEDIATE RELEASE

Contact Information

At GeoVax Labs, Inc.
Andrew Kandalepas
V.P. Corporate Finance
847-303-6566

At Financial Relations Board
Analyst Inquiries
John Waelti
312-640-6760

Media Inquiries
Melanie Nimrodi
312-546-3508

**GEOVAX LABS, INC. ANNOUNCES LISTING ON
OTC BULLETIN BOARD**

November 9, 2006, Atlanta, Ga. – GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company, announced today that its common stock has begun trading on the OTC Bulletin Board (“OTC BB”) under the symbol “GOVX.” The OTC BB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter equity securities.

“This is an important early milestone in our efforts to raise investor awareness,” said Donald Hildebrand, CEO and Chairman of GeoVax Labs. “Moving to the OTC BB should improve our ability to attract institutional investors and advance our AIDS vaccine development program.”

About GeoVax Labs, Inc:

GeoVax, Inc. merged with Dauphin Technology on September 28, 2006 to become GeoVax Labs, Inc. GeoVax, Inc., a wholly-owned subsidiary of GeoVax Labs, Inc., was formed in 2001, and specializes in the development of human vaccines, with a particular focus on the creation, testing, manufacturing, human trial evaluation and licensing of HIV/AIDS vaccines. GeoVax Labs technology has been developed over the past 12 years. It has been tested in primates where it was 100% effective in one study and 96% effective in another. GeoVax Labs has satisfactorily completed one AIDS vaccine human trial and is currently conducting two human trials with two additional trials scheduled to start in the near future. More information on the company may be found on its website at www.geovax.com.

###